PAVmed (PAVM) versus The Competition Head to Head Survey

PAVmed (NASDAQ:PAVM) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its peers? We will compare PAVmed to related companies based on the strength of its profitability, earnings, analyst recommendations, valuation, risk, institutional ownership and dividends.

Earnings and Valuation

This table compares PAVmed and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
PAVmed	$70,000.00	$400,000.00	-0.10
PAVmed Competitors	$1.88 billion	$139.14 million	12.55

PAVmed’s peers have higher revenue and earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

PAVmed has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, PAVmed’s peers have a beta of 2.57, indicating that their average stock price is 157% more volatile than the S&P 500.

Profitability

This table compares PAVmed and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PAVmed	-10,794.64%	-126.43%	-25.49%
PAVmed Competitors	-276.78%	-149.08%	-21.73%

Institutional and Insider Ownership

19.9% of PAVmed shares are owned by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 13.4% of PAVmed shares are owned by insiders. Comparatively, 15.0% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for PAVmed and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1	1	1	0	2.00
PAVmed Competitors	4284	10561	18338	830	2.46

PAVmed currently has a consensus target price of $56.00, indicating a potential upside of 3,335.58%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 18.58%. Given PAVmed’s higher possible upside, equities research analysts clearly believe PAVmed is more favorable than its peers.

Summary

PAVmed peers beat PAVmed on 10 of the 12 factors compared.

PAVmed Company Profile

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.